Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Screening for prostate cancer: evidence, ongoing trials, policies and knowledge gaps.
BMJ Oncol
April 2023
Department of Urology, Cancer Institute, Erasmus University Rotterdam, Rotterdam, Zuid-Holland, Netherlands.
Long-term screening with serum prostate-specific antigen (PSA) and systematic prostate biopsies can reduce prostate cancer mortality but leads to unacceptable overdiagnosis. Over the past decade, diagnostic methods have improved and the indolent nature of low-grade prostate cancer has been established. These advances now enable more selective detection of potentially lethal prostate cancer.
View Article and Find Full Text PDFLINC01322 may serve as a potential diagnostic marker for advanced stage tumors in renal cell carcinoma patients eligible for total nephrectomy.
Biochem Biophys Rep
December 2024
Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Background: Renal cell carcinoma (RCC) is a common urological cancer globally and shows a favorable prognosis in early stages of the tumor progression. Due to the poor prognosis for metastatic RCC patients, it is crucial to explore the molecular biology of RCC progression to establish efficient diagnostic and therapeutic markers for these patients. Long non-coding RNAs (lncRNAs) have critical roles in regulation of tumor cell proliferation, migration, and apoptosis during RCC progression.
View Article and Find Full Text PDFObjective: We report post hoc analyses of efficacy with first-line avelumab plus axitinib or sunitinib according to baseline neutrophil-to-eosinophil ratio (NER) in patients with advanced renal cell carcinoma (aRCC) from the JAVELIN Renal 101 phase 3 trial.
Methods And Analysis: Progression-free survival (PFS), overall survival (OS) and objective response per baseline NER were analysed in the overall population and in patients with programmed death ligand 1 (PD-L1+) tumours. Multivariable Cox regression analyses to assess the effect of NER after adjustment for other baseline variables were conducted.
Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligence.
Nat Cancer
January 2025
Institute for Artificial Intelligence in Medicine, University Hospital Essen (AöR), Essen, Germany.
Despite advances in precision oncology, clinical decision-making still relies on limited variables and expert knowledge. To address this limitation, we combined multimodal real-world data and explainable artificial intelligence (xAI) to introduce AI-derived (AID) markers for clinical decision support. We used xAI to decode the outcome of 15,726 patients across 38 solid cancer entities based on 350 markers, including clinical records, image-derived body compositions, and mutational tumor profiles.
View Article and Find Full Text PDFDigital twin driven electrode optimization for wearable bladder monitoring via bioimpedance.
NPJ Digit Med
January 2025
School of Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta, GA, USA.
Monitoring fluid intake and output for congestive heart failure (CHF) patients is an essential tool to prevent fluid overload, a principal cause of hospital admissions. Addressing this, bladder volume measurement systems utilizing bioimpedance and electrical impedance tomography have been proposed, with limited exploration of continuous monitoring within a wearable design. Advancing this format, we developed a conductivity digital twin from radiological data, where we performed exhaustive simulations to optimize electrode sensitivity on an individual basis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!